logo
Plus   Neg
Share
Email

Akebia Therapeutics, Vifor Pharma Expand License Agreement For Vadadustat

Akebia Therapeutics, Inc. (AKBA) and Switzerland-based Vifor Pharma Group announced Tuesday that the companies have amended the terms of their license agreement to sell vadadustat to Fresenius Medical Care (FMS) North America dialysis clinics in the United States, subject to its approval by the U.S. Food and Drug Administration.

Vadadustat is an oral hypoxia-inducible factor or HIF prolyl hydroxylase inhibitor currently in global Phase III development for the treatment of anemia due to chronic kidney disease or CKD.

Under the terms of the agreement signed in May 2017, Akebia granted Vifor Pharma a license to sell vadadustat to Fresenius Medical Care North America for use solely within its dialysis clinics in the U.S., subject to FDA approval. The license has now been amended to allow Vifor Pharma to also sell vadadustat to certain third-party dialysis organizations, for use in the U.S., thereby expanding the potential opportunity for vadadustat under the agreement to up to 60% of U.S. dialysis patients.

Under the terms of the amended agreement, Akebia is eligible to receive an additional $5 million payment, which means Akebia is eligible to receive a total payment of $25 million from Vifor Pharma upon approval of vadadustat by the FDA and the earlier of CMS's determination that vadadustat will be reimbursed under the TDAPA or included in the ESRD bundle.

The license, which is subject to vadadustat's approval by the FDA and inclusion in the Centres for Medicare & Medicaid (CMS) End Stage Renal Disease Prospective Payment System, will now also be effective during the Transitional Drug Add-on Payment Adjustment (TDAPA) two-year period that is expected to precede the ESRD bundle period.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The Federal Trade Commission said it will challenge the proposed merger between two Philadelphia-area hospital systems as the deal could reduce competition, resulting in raised prices in both Philadelphia and Montgomery counties. The FTC issued an administrative complaint to block the proposed merger of Jefferson Health and Albert Einstein Healthcare Network. Step2 Co. LLC recalled about 20,500 units of Little Helper's children's grocery shopping carts for possible laceration hazard, the U.S. Consumer Product Safety Commission said in a statement. These include about 3,500 units sold in Canada. The company said the shopping cart's basket can break into sharp pieces, leading to a laceration hazard. Wendy's Co. joined the growing list of fast-food chains that are launching plant-based meat options. The fast food chain has introduced "The Plantiful," a plant-based burger, at its restaurants across Canada. Wendy's said it formulated its own recipe in-house, unlike other fast-food chains who have relied on Beyond Meat or Impossible Foods to introduce their plant-based meat alternatives.
RELATED NEWS
Follow RTT
>